2016 - Nurturing the idea
nature of chronic conditions, a lean team
of five gets together to develop the Wellthy
Therapeutics product concept. Our first therapy
targeting individuals diagnosed with type 2
diabetes is deployed via WhatsApp. Following
its success, an engineering team is assembled.
2017 - Recognition for our results
GrowX, BeeNext and Ranjan Pai, roll out our first
MVP. More testing follows - 13 pilots to be precise.
Our results begin to speak for themselves.
Our first product gets endorsed by the Research
Society for the Study of Diabetes in India (RSSDI)
as a prescription grade platform for type-II diabetes.
A big win!
2018 - Onboarding our first
advisory board to vet the product at every step.
Innovation and hard work pays off and we enter
into a distribution agreement with Roche
AccuChek to expand our impact to reach their
patient base. More partners join in.
2019 - Growing our impact base
patients, we sign a strategic and commercial
partnership with Cipla, through which we
expand our therapies into Hypertension and
Dyslipidemia. We also partner with several other
pharma players including Novartis, and enter the
South Asian market with Aviva, our Singa
2020 - Fueling expansion plans
patients, we deepen our expertise in Cardiology
with new products in Congestive Heart
Failure and Ischemic Heart Disease. Backed by
Indian Pharma’s respiratory market leader, we
enter a new therapy area with a product in
asthma. Our results continue to grow and stand
at 20+ clinical publications recognised globally.
We empower patients to
achieve their health goals
one step at a time
Meet our team
VP – Enterprise Partnerships
VP – Design and Engineering
VP – Account Management
Dr. Jitesh Bhatt
VP – Clinical Product
VP – Finance
VP – Care Delivery
Dr. Sid Kolwankar
AVP – Clinical Intelligence
Dr. Abhijeet Kanetkar
VP – Insurance Business